Novo Nordisk: Riding High on Diabetes
Novo Nordisk is confident that it can continue to generate strong growth from its leading diabetes franchise. Having exited oral anti-diabetics, it's betting on further innovation in insulin and on a strong entry into the GLP-1 analog space.
You may also be interested in...
Novo Nordisk AS says it won’t seek the highest price it believes its next-generation insulins, the ultra-long-acting Degludec and Degludec Plus, could command on the basis of health economic data alone.
With most eyes fixed on the imminent arrival of biosimilar antibodies – billed as the most valuable copy-cat biologics, given originators' high prices – it may be easy to overlook the potential of first-generation biosimilars such as insulin.
In a bid to protect its most valuable product, Lantus, Sanofi’s new diabetes division intends to provide holistic solutions in an effort to help patients better manage their disease. Will it work?